Aduhelm是阿尔茨海默氏新药, FDA approves Aduhelm, a new Alzheimer's drug, amid debate over its efficacy and high cost.

林业发展局已经批准了Aduhelm,一种治疗阿尔茨海默氏病的新药物,这是首例此类疗法。 The FDA has approved Aduhelm, a new drug for Alzheimer's disease, marking the first therapy of its kind. 由Biogen和Eisai开发的Aduhelm通过静脉注射来减少大脑中的氨基类贝塔斑块。 Developed by Biogen and Eisai, Aduhelm reduces amyloid-beta plaques in the brain and is administered through intravenous infusions. 尽管一些人称其为突破性突破,但这一批准引发了关于药物的功效和成本的辩论,需要进行进一步的研究以证实其临床效益。 While hailed as a breakthrough by some, the approval has sparked debate over the drug's efficacy and cost, with further studies required to confirm its clinical benefits.